Published in Neurosurgery on September 01, 2003
Tumor heterogeneity is an active process maintained by a mutant EGFR-induced cytokine circuit in glioblastoma. Genes Dev (2010) 3.99
Emerging insights into the molecular and cellular basis of glioblastoma. Genes Dev (2012) 3.44
Development of a novel mouse glioma model using lentiviral vectors. Nat Med (2009) 3.08
Modeling Adult Gliomas Using RCAS/t-va Technology. Transl Oncol (2009) 1.89
Genetic modeling of gliomas in mice: new tools to tackle old problems. Glia (2011) 1.28
In vivo models of primary brain tumors: pitfalls and perspectives. Neuro Oncol (2012) 1.21
Hypoxia-induced mixed-lineage leukemia 1 regulates glioma stem cell tumorigenic potential. Cell Death Differ (2011) 1.07
Glioma stem cell maintenance: the role of the microenvironment. Curr Pharm Des (2011) 0.93
A novel technique of serial biopsy in mouse brain tumour models. PLoS One (2017) 0.75
CSF-1R inhibition alters macrophage polarization and blocks glioma progression. Nat Med (2013) 5.04
PTEN/PI3K/Akt pathway regulates the side population phenotype and ABCG2 activity in glioma tumor stem-like cells. Cell Stem Cell (2009) 4.94
A brain tumor molecular imaging strategy using a new triple-modality MRI-photoacoustic-Raman nanoparticle. Nat Med (2012) 4.64
Differential exoprotease activities confer tumor-specific serum peptidome patterns. J Clin Invest (2006) 4.37
The PTEN-regulating microRNA miR-26a is amplified in high-grade glioma and facilitates gliomagenesis in vivo. Genes Dev (2009) 4.15
Targeting brain cancer: advances in the molecular pathology of malignant glioma and medulloblastoma. Nat Rev Cancer (2010) 4.10
Oncogenic Ras and Akt signaling contribute to glioblastoma formation by differential recruitment of existing mRNAs to polysomes. Mol Cell (2003) 3.68
PI3K pathway regulates survival of cancer stem cells residing in the perivascular niche following radiation in medulloblastoma in vivo. Genes Dev (2008) 3.50
Genomic analysis of non-NF2 meningiomas reveals mutations in TRAF7, KLF4, AKT1, and SMO. Science (2013) 3.45
Perivascular nitric oxide activates notch signaling and promotes stem-like character in PDGF-induced glioma cells. Cell Stem Cell (2010) 3.34
Intratumoral heterogeneity of receptor tyrosine kinases EGFR and PDGFRA amplification in glioblastoma defines subpopulations with distinct growth factor response. Proc Natl Acad Sci U S A (2012) 3.12
Mouse models of brain tumors and their applications in preclinical trials. Clin Cancer Res (2006) 2.68
Somatic mutations of the Parkinson's disease-associated gene PARK2 in glioblastoma and other human malignancies. Nat Genet (2009) 2.51
Self-renewal does not predict tumor growth potential in mouse models of high-grade glioma. Cancer Cell (2012) 2.50
Molecular study of malignant gliomas treated with epidermal growth factor receptor inhibitors: tissue analysis from North American Brain Tumor Consortium Trials 01-03 and 00-01. Clin Cancer Res (2005) 2.46
Ink4a-Arf loss cooperates with KRas activation in astrocytes and neural progenitors to generate glioblastomas of various morphologies depending on activated Akt. Cancer Res (2002) 2.45
Dose-dependent effects of platelet-derived growth factor-B on glial tumorigenesis. Cancer Res (2004) 2.36
The brain tumor microenvironment. Glia (2011) 2.13
Serum peptide profiling by magnetic particle-assisted, automated sample processing and MALDI-TOF mass spectrometry. Anal Chem (2004) 2.07
mTOR promotes survival and astrocytic characteristics induced by Pten/AKT signaling in glioblastoma. Neoplasia (2005) 2.04
Genetically engineered models have advantages over xenografts for preclinical studies. Cancer Res (2006) 2.01
Preclinical evaluation of radiation and perifosine in a genetically and histologically accurate model of brainstem glioma. Cancer Res (2010) 1.97
Sonic hedgehog and insulin-like growth factor signaling synergize to induce medulloblastoma formation from nestin-expressing neural progenitors in mice. Oncogene (2004) 1.96
Modeling Adult Gliomas Using RCAS/t-va Technology. Transl Oncol (2009) 1.89
PDGFRA gene rearrangements are frequent genetic events in PDGFRA-amplified glioblastomas. Genes Dev (2010) 1.82
Gene expression microarray analysis reveals YKL-40 to be a potential serum marker for malignant character in human glioma. Cancer Res (2002) 1.82
Dissecting tumor maintenance requirements using bioluminescence imaging of cell proliferation in a mouse glioma model. Nat Med (2004) 1.76
Notch signaling enhances nestin expression in gliomas. Neoplasia (2006) 1.73
Radiation resistance and stem-like cells in brain tumors. Cancer Cell (2006) 1.70
Loss of ATM/Chk2/p53 pathway components accelerates tumor development and contributes to radiation resistance in gliomas. Cancer Cell (2010) 1.68
Molecular imaging of Akt kinase activity. Nat Med (2007) 1.68
The role of radiotherapy following gross-total resection of atypical meningiomas. J Neurosurg (2012) 1.67
Cancer stem cells and survival pathways. Cell Cycle (2008) 1.66
The brain tumor microenvironment. Glia (2012) 1.66
Genetically engineered mouse models of brain cancer and the promise of preclinical testing. Brain Pathol (2009) 1.66
Allelic losses at 1p36 and 19q13 in gliomas: correlation with histologic classification, definition of a 150-kb minimal deleted region on 1p36, and evaluation of CAMTA1 as a candidate tumor suppressor gene. Clin Cancer Res (2005) 1.65
Insulin-like growth factor binding protein 2 promotes glioma development and progression. Proc Natl Acad Sci U S A (2007) 1.61
Gli activity correlates with tumor grade in platelet-derived growth factor-induced gliomas. Cancer Res (2008) 1.60
p27 deficiency is associated with migration defects in PDGF-expressing gliomas in vivo. Cell Cycle (2010) 1.59
Postgenomic global analysis of translational control induced by oncogenic signaling. Oncogene (2004) 1.58
YKL-40 and matrix metalloproteinase-9 as potential serum biomarkers for patients with high-grade gliomas. Clin Cancer Res (2006) 1.53
Platelet-derived growth factor (PDGF) and glial tumorigenesis. Cancer Lett (2005) 1.53
Splicing factor hnRNPH drives an oncogenic splicing switch in gliomas. EMBO J (2011) 1.49
Magnetic resonance imaging determination of tumor grade and early response to temozolomide in a genetically engineered mouse model of glioma. Clin Cancer Res (2007) 1.48
Cell type-specific tumor suppression by Ink4a and Arf in Kras-induced mouse gliomagenesis. Cancer Res (2005) 1.47
Perifosine inhibits multiple signaling pathways in glial progenitors and cooperates with temozolomide to arrest cell proliferation in gliomas in vivo. Cancer Res (2005) 1.46
Defining future directions in spinal cord tumor research: proceedings from the National Institutes of Health workshop. J Neurosurg Spine (2010) 1.45
miR-34a repression in proneural malignant gliomas upregulates expression of its target PDGFRA and promotes tumorigenesis. PLoS One (2012) 1.44
c-Myc enhances sonic hedgehog-induced medulloblastoma formation from nestin-expressing neural progenitors in mice. Neoplasia (2003) 1.40
Sonic hedgehog pathway activation is induced by acute brain injury and regulated by injury-related inflammation. J Neurosci (2009) 1.38
Recruited cells can become transformed and overtake PDGF-induced murine gliomas in vivo during tumor progression. PLoS One (2011) 1.37
Constitutive activation of Raf-1 induces glioma formation in mice. Neoplasia (2008) 1.36
Inferring transcriptional and microRNA-mediated regulatory programs in glioblastoma. Mol Syst Biol (2012) 1.36
DNA damage response and growth factor signaling pathways in gliomagenesis and therapeutic resistance. Cancer Res (2011) 1.33
A physical sciences network characterization of non-tumorigenic and metastatic cells. Sci Rep (2013) 1.33
The perivascular niche microenvironment in brain tumor progression. Cell Cycle (2010) 1.30
Glioma formation, cancer stem cells, and akt signaling. Stem Cell Rev (2008) 1.30
Genetic modeling of gliomas in mice: new tools to tackle old problems. Glia (2011) 1.28
Dissection of the c-Kit signaling pathway in mouse primordial germ cells by retroviral-mediated gene transfer. Proc Natl Acad Sci U S A (2002) 1.26
An activated mutant BRAF kinase domain is sufficient to induce pilocytic astrocytoma in mice. J Clin Invest (2011) 1.25
The ABCG2 resistance network of glioblastoma. Cell Cycle (2009) 1.24
Malignant gliomas with primitive neuroectodermal tumor-like components: a clinicopathologic and genetic study of 53 cases. Brain Pathol (2008) 1.18
p190RhoGAP can act to inhibit PDGF-induced gliomas in mice: a putative tumor suppressor encoded on human chromosome 19q13.3. Genes Dev (2003) 1.16
Candidate pathways for promoting differentiation or quiescence of oligodendrocyte progenitor-like cells in glioma. Cancer Res (2012) 1.15
Platelet-derived growth factor-mediated gliomagenesis and brain tumor recruitment. Neurosurg Clin N Am (2007) 1.15
The characteristics of astrocytomas and oligodendrogliomas are caused by two distinct and interchangeable signaling formats. Neoplasia (2005) 1.12
Perifosine and CCI 779 co-operate to induce cell death and decrease proliferation in PTEN-intact and PTEN-deficient PDGF-driven murine glioblastoma. PLoS One (2011) 1.12
Incorporating molecular tools into clinical trials and treatment for gliomas? Curr Opin Neurol (2007) 1.11
Activated EGFR signaling increases proliferation, survival, and migration and blocks neuronal differentiation in post-natal neural stem cells. J Neurooncol (2009) 1.11
Early detection and prognosis of ovarian cancer using serum YKL-40. J Clin Oncol (2004) 1.09
MRI of mouse models for gliomas shows similarities to humans and can be used to identify mice for preclinical trials. Neoplasia (2002) 1.08
A mathematical methodology for determining the temporal order of pathway alterations arising during gliomagenesis. PLoS Comput Biol (2012) 1.07
MYC expression promotes the proliferation of neural progenitor cells in culture and in vivo. Neoplasia (2002) 1.06
Astrocyte-specific expression patterns associated with the PDGF-induced glioma microenvironment. PLoS One (2012) 1.03
Huntingtin interacting protein 1 is a novel brain tumor marker that associates with epidermal growth factor receptor. Cancer Res (2007) 1.02
Tuberous sclerosis complex suppression in cerebellar development and medulloblastoma: separate regulation of mammalian target of rapamycin activity and p27 Kip1 localization. Cancer Res (2009) 1.01
Serum YKL-40 is a marker of prognosis and disease status in high-grade gliomas. Neuro Oncol (2011) 1.00
The therapeutic implications of plasticity of the cancer stem cell phenotype. PLoS One (2010) 0.99
MYCN and MYC regulate tumor proliferation and tumorigenesis directly through BMI1 in human neuroblastomas. FASEB J (2011) 0.98
Stem cells and brain cancer. Exp Cell Res (2005) 0.98
DW-MRI as a biomarker to compare therapeutic outcomes in radiotherapy regimens incorporating temozolomide or gemcitabine in glioblastoma. PLoS One (2012) 0.96
Astrocyte differentiation states and glioma formation. Cancer J (2003) 0.96
New strategy for the analysis of phenotypic marker antigens in brain tumor-derived neurospheres in mice and humans. Neurosurg Focus (2008) 0.95
Origins of brain tumors--a disease of stem cells? Nat Clin Pract Neurol (2006) 0.95
YKL-40 and MMP-9 as serum markers for patients with primary central nervous system lymphoma. Ann Neurol (2011) 0.94
Validation of a high-content screening assay using whole-well imaging of transformed phenotypes. Assay Drug Dev Technol (2010) 0.94
Overexpression of c-MYC promotes an undifferentiated phenotype in cultured astrocytes and allows elevated Ras and Akt signaling to induce gliomas from GFAP-expressing cells in mice. Neuron Glia Biol (2004) 0.94
In vivo radiation response of proneural glioma characterized by protective p53 transcriptional program and proneural-mesenchymal shift. Proc Natl Acad Sci U S A (2014) 0.93
Guiding brain tumor resection using surface-enhanced Raman scattering nanoparticles and a hand-held Raman scanner. ACS Nano (2014) 0.93
Dynamic small-animal PET imaging of tumor proliferation with 3'-deoxy-3'-18F-fluorothymidine in a genetically engineered mouse model of high-grade gliomas. J Nucl Med (2008) 0.92
Yin and yang: cancer-implicated miRNAs that have it both ways. Cell Cycle (2009) 0.92
MEF promotes stemness in the pathogenesis of gliomas. Cell Stem Cell (2012) 0.92
Cooperative translational control of gene expression by Ras and Akt in cancer. Trends Mol Med (2004) 0.91
Developmental neurobiology and the origin of brain tumors. J Neurooncol (2004) 0.91
Applications of mouse glioma models in preclinical trials. Mutat Res (2005) 0.91
Identification of global alteration of translational regulation in glioma in vivo. PLoS One (2012) 0.91
PDGF in gliomas: more than just a growth factor? Ups J Med Sci (2012) 0.88
Organ donors with malignant gliomas: an update. Am J Transplant (2004) 0.87
Cyclin D1 and cdk4 mediate development of neurologically destructive oligodendroglioma. Cancer Res (2011) 0.86
Protein phosphatase 2A mediates dormancy of glioblastoma multiforme-derived tumor stem-like cells during hypoxia. PLoS One (2012) 0.86